ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 5L

Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomized, Placebo-Controlled, Dose-Ranging Study

Désirée van der Heijde1, Atul A Deodhar2, James C Wei3, Edit Drescher4, Dona Fleishaker5, Thijs Hendrikx6, David Li6, Sujatha Menon5 and Keith S Kanik5, 1Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 3Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan, 4Csolnoky Ferenc Hospital, Veszprém, Hungary, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, Collegeville, PA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: October 27, 2015

Keywords: Ankylosing spondylitis (AS), Late-Breaking 2015, randomized trials and tofacitinib

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: ACR Late-breaking Abstract Session

Session Type: ACR Late-breaking Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:
This was the first investigation of the
effects of tofacitinib (TOFA) in adult patients (pts) with active ankylosing
spondylitis (AS). TOFA is an oral Janus kinase inhibitor under investigation
for the treatment of AS.

Methods: This was a 16-week
(wk), Phase 2, multicenter, randomized, double-blind, placebo (PBO)-controlled,
dose-ranging study (NCT01786668) to investigate efficacy, safety, and
dose-response of TOFA in pts with AS. Pts fulfilling the modified New York
criteria (central read) were randomized 1:1:1:1 to PBO or TOFA 2, 5, or 10 mg
twice daily (BID) for 12 wks plus 4 wks follow-up. The primary efficacy
endpoint was ASAS20 response rate at Wk 12 using a 3-parameter Bayesian Emax
model by assuming a monotonic response. Secondary endpoints included ASAS40
response rate, AS disease activity score using C-reactive protein (ASDAS), Bath
AS disease activity index 50% (BASDAI50) response rate, Bath AS functional
index, Bath AS metrology index (linear method), Spondyloarthritis Research Consortium
of Canada (SPARCC) score of sacroiliac (SI) joints and spine. Safety endpoints
included adverse event (AE), and laboratory outcomes.

Results: 208 pts were
randomized and 207 treated; 196 pts completed the study. 51 pts in the PBO
group and 52 in each TOFA group were included in analyses. Baseline
demographics and disease characteristics were balanced in general between
groups and typical of AS populations (87.4% HLA-B27 positive; 81.2% white;
69.1% male; mean age 42 years; mean disease duration 6.3 years; mean BASDAI 6.7).

The Table summarizes efficacy results. The ASAS20 Emax
model showed TOFA 10 mg BID had a high response rate and its confidence
bounds met a pre-specified efficacy decision rule. Observed ASAS20 response
rates were significantly greater with TOFA 5 mg BID vs PBO, compared with
2 or 10 mg BID. All TOFA groups had ASAS40, ASDAS, and BASDAI50 improvements of
similar magnitude vs PBO. TOFA 2 mg BID did not differ vs PBO in remaining
clinical efficacy measures or SPARCC scores. TOFA 5 and 10 mg BID had greater
clinical efficacy vs PBO, with minimal differences between doses, and
significantly improved SPARCC SI joint and spine scores vs PBO.

The
Table summarizes safety results. No TOFA-related safety issues unique to the AS
population or new safety concerns were identified. Two treatment-related herpes
zoster cases were reported (1 each with TOFA 2 and 10 mg BID). No cases of
tuberculosis, malignancy, gastrointestinal perforation, or death were reported.
Dose-dependent changes in laboratory outcomes commonly reported in other TOFA
studies were observed and returned to approximately baseline values by Wk 16.

Conclusion:
TOFA 5 and 10 mg BID demonstrated greater clinical and imaging efficacy vs PBO in
reducing the signs and symptoms of AS in adults with active AS. Safety was
similar to that reported for TOFA studies in other indication

 

Table. Summary of efficacy and safety endpoints

 

Placebo

(n=51)

TOFA

2 mg BID

(n=52)

TOFA

5 mg BID

(n=52)

TOFA

10 mg BID

(n=52)

Primary endpoint ASAS20 Emax model estimatesa

     ASAS20 response rate, %

40.1

56.0

63.0

67.4

     ASAS20 response rate vs placebo, %

     50% credible interval

     60% credible interval

     95% credible interval

N/A

15.8

(11.1, 19.9)

(10.2, 21.2)

(5.0, 30.3)

22.9

(17.8, 28.0)

(16.5, 29.3)

(8.4, 37.7)

27.3

(21.8, 33.0)

(20.3, 34.4)

(10.7, 43.4)

Secondary efficacy endpoints at Wk 12

ASAS20 response rate (%), observeda

41.2

51.9

80.8***

55.8

ASAS40 response rate (%), observeda

19.6

42.3*

46.2**

38.5*

CBL in ASDAS, LS mean (SE)

-0.7 (0.1)

-1.2 (0.1)**

-1.4 (0.1)***

-1.4 (0.1)***

BASDAI50 response rate (%), observeda

23.5

46.2*

42.3*

42.3*

CBL in BASFI, LS mean (SE)

-1.4 (0.3)

-1.9 (0.3)

-2.4 (0.3)*

-2.2 (0.3)*

CBL in BASMI, LS mean (SE)

-0.2 (0.1)

-0.3 (0.1)

-0.4 (0.1)

-0.6 (0.1)*

CBL in SPARCC MRI of the SI joints, LS mean (SE)

-0.8 (0.8)

-1.7 (0.8)

-3.2 (0.8)*

-3.6 (0.8)*

CBL in SPARCC MRI of the spine, LS mean (SE)

-0.1 (1.1)

-3.1 (1.1)

-5.5 (1.1)***

-6.6 (1.1)***

Safety endpoints

TEAEs, n (%)

22 (43.1)

23 (44.2)

28 (53.8)

27 (51.9)

     Treatment related

14 (27.5)

14 (26.9)

12 (23.1)

14 (26.9)

Serious AEs, n (%)

2 (3.9)

0

1 (1.9)

1 (1.9)

     Treatment related

1 (2.0)b

0

0

0

Discontinuations due to AEs, n (%)

3 (5.9)

0

1 (1.9)

1 (1.9)

     Treatment related

2 (3.9)c

0

1 (1.9)c

1 (1.9)c

AST >3x ULN, n (%)

1 (2.0)

0

3 (5.8)

0

ALT >3x ULN, n (%)

1 (2.0)

0

2 (3.8)

1 (2.0)

Wk 12 CBL in serum creatinine, g/dL, mean (SD)

0.0 (0.1)

0.0 (0.1)

0.0 (0.1)

0.1 (0.1)

Wk 12% CBL in LDL-C, mean (SD)

-1.2 (15.8)

7.2 (13.5)

9.6 (21.0)

23.5 (28.3)

Wk 12% CBL in HDL-C, mean (SD)

1.0 (17.4)

10.0 (15.1)

11.0 (18.6)

18.5 (17.0)

Wk 12 CBL in ANC, cells 103/mm3, mean (SD)

-0.3 (1.2)

-0.3 (1.6)

-0.3 (1.4)

-0.9 (1.6)

Wk 12 CBL in ALC, cells 103/mm3, mean (SD)

0.0 (0.4)

0.1 (0.4)

-0.1 (0.4)

0.0 (0.4)

Wk 12 CBL in Hb, g/dL, mean (SD)

-0.2 (0.6)

0.1 (0.6)

0.3 (0.7)

0.1 (0.9)

*p<0.05, **p<0.01, ***p<0.001

aNRI/LOCF

bvertigo

cspinal pain (placebo), hypertransaminasemia (placebo), peripheral swelling (TOFA 5 mg BID), herpes zoster (TOFA 10 mg BID)

d50, 51, 52, and 50 patients receiving PBO, and TOFA 2, 5, and 10 mg BID, respectively were included in this analysis.

AE, adverse event; ALC, absolute lymphocyte count; ALT, alanine aminotransferase; ANC, absolute neutrophil count; ASAS, assessments in ankylosing spondylitis improvement; ASDAS, ankylosing spondylitis disease activity score using C-reactive protein; AST, aspartate aminotransferase; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index (linear method); BID, twice daily; CBL, change from baseline; Hb, hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LOCF, last observation carried forward; LS, least squares; N/A, not applicable; NRI, non-responder imputation; SD, standard deviation; SE, standard error; SPARCC, spondyloarthritis research consortium of Canada; TEAE, treatment-emergent AE; TOFA, tofacitinib; ULN, upper limit of normal; Wk, week.

 


Disclosure: D. van der Heijde, AbbVie, Amgen, AstraZeneca, Augurex, BMS, Boehringer Ingelheim, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly, Galapagos, GSK, Janssen Biologics, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer Inc, Roche, Sanofi-Aventis, UCB, Vertex, 5,Imaging Rheumatology, 9; A. A. Deodhar, AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB, 2,AbbVie, Boehringer Ingelheim, Janssen, Novartis, Pfizer Inc, and UCB, 9; J. C. Wei, AbbVie, Bristol Myers Squibb, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer Inc, Sanofi-Aventis, TSH Taiwan, and UCB, 2,AbbVie, Bristol Myers Squibb, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer Inc, Sanofi-Aventis, TSH Taiwan, and UCB, 5; E. Drescher, Eli Lilly, 9; D. Fleishaker, Pfizer Inc, 1,Pfizer Inc, 3; T. Hendrikx, Pfizer Inc, 1,Pfizer Inc, 3; D. Li, Pfizer Inc, 1,Pfizer Inc, 3; S. Menon, Pfizer Inc, 1,Pfizer Inc, 3; K. S. Kanik, Pfizer Inc, 1,Pfizer Inc, 3.

To cite this abstract in AMA style:

van der Heijde D, Deodhar AA, Wei JC, Drescher E, Fleishaker D, Hendrikx T, Li D, Menon S, Kanik KS. Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomized, Placebo-Controlled, Dose-Ranging Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/tofacitinib-in-patients-with-ankylosing-spondylitis-a-phase-2-16-week-randomized-placebo-controlled-dose-ranging-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tofacitinib-in-patients-with-ankylosing-spondylitis-a-phase-2-16-week-randomized-placebo-controlled-dose-ranging-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology